메뉴 건너뛰기
The Lancet Neurology
Volumn 14, Issue 11, 2015, Pages 1066-1067
CGRP antibodies: The Holy Grail for migraine prevention?
Author keywords

[No Author keywords available]
Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; PEPTIDE ANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;
EID: 84944037787     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00244-6     Document Type: Note
Times cited : (13)
References (9)
  • 1
    • 84871051576 scopus 로고    scopus 로고
    • Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
    • Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
    • (2012) Lancet , vol.380 , pp. 2163-2196
    • Vos, T.1    Flaxman, A.D.2    Naghavi, M.3
  • 2
    • 80054734731 scopus 로고    scopus 로고
    • OnabotulinumtoxinA for treatment of chronic migraine: pooled analysis of the 56-week PREEMPT clinical program
    • Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analysis of the 56-week PREEMPT clinical program. Headache 2011, 51:1358-1373.
    • (2011) Headache , vol.51 , pp. 1358-1373
    • Aurora, S.K.1    Winner, P.2    Freeman, M.C.3
  • 3
    • 84907964596 scopus 로고    scopus 로고
    • Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
    • Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014, 13:1100-1107.
    • (2014) Lancet Neurol , vol.13 , pp. 1100-1107
    • Dodick, D.W.1    Goadsby, P.J.2    Silberstein, S.D.3
  • 4
    • 84906262129 scopus 로고    scopus 로고
    • Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
    • Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, 13:885-892.
    • (2014) Lancet Neurol , vol.13 , pp. 885-892
    • Dodick, D.W.1    Goadsby, P.J.2    Spierings, E.L.3
  • 5
    • 84944059855 scopus 로고    scopus 로고
    • Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
    • published online Sept 30.
    • Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015, published online Sept 30. http://dx.doi.org/10.1016/S1474-4422(15)00249-5.
    • (2015) Lancet Neurol
    • Bigal, M.E.1    Dodick, D.W.2    Rapoport, A.M.3
  • 6
    • 84944039741 scopus 로고    scopus 로고
    • Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
    • published online Sept 30.
    • Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015, published online Sept 30. http://dx.doi.org/10.1016/S1474-4422(15)00245-8.
    • (2015) Lancet Neurol
    • Bigal, M.E.1    Edvinsson, L.2    Rapoport, A.M.3
  • 7
    • 84888324384 scopus 로고    scopus 로고
    • Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
    • Cernuda-Morollón E, Larrosa D, Ramón C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013, 81:1191-1196.
    • (2013) Neurology , vol.81 , pp. 1191-1196
    • Cernuda-Morollón, E.1    Larrosa, D.2    Ramón, C.3
  • 8
    • 84924808806 scopus 로고    scopus 로고
    • Increased VIP levels outside migraine attacks as a marker for parasympathetic activation in chronic migraine
    • Cernuda-Morollón E, Alvarez R, Larrosa D, et al. Increased VIP levels outside migraine attacks as a marker for parasympathetic activation in chronic migraine. Cephalalgia 2015, 35:310-316.
    • (2015) Cephalalgia , vol.35 , pp. 310-316
    • Cernuda-Morollón, E.1    Alvarez, R.2    Larrosa, D.3
  • 9
    • 84918564033 scopus 로고    scopus 로고
    • Site of effect of LY2951742 for migraine prophylaxis
    • Tfelt-Hansen P Site of effect of LY2951742 for migraine prophylaxis. Lancet Neurol 2015, 14:31-32.
    • (2015) Lancet Neurol , vol.14 , pp. 31-32
    • Tfelt-Hansen, P.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.